+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia

An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia

Blood 121(7): 1200-1208

Mutations in HFE lead to hereditary hemochromatosis (HH) because of inappropriately high iron uptake from the diet resulting from decreased hepatic expression of the iron-regulatory hormone hepcidin. -thalassemia is a congenital anemia caused by partial or complete loss of -globin synthesis causing ineffective erythropoiesis, anemia, decreased hepcidin production, and secondary iron overload. Tmprss6 is postulated to regulate hepcidin production by cleaving Hemojuvelin (Hjv), a key modulator of hepcidin expression, from the hepatocyte surface. On this basis, we hypothesized that treatment of mouse models of HH (Hfe(-/-)) and -thalassemia intermedia (Hbb(th3/+)) with Tmprss6 siRNA formulated in lipid nanoparticles (LNPs) that are preferentially taken up by the liver would increase hepcidin expression and lessen the iron loading in both models. In the present study, we demonstrate that LNP-Tmprss6 siRNA treatment of Hfe(-/-) and Hbb(th3/+) mice induces hepcidin and diminishes tissue and serum iron levels. Furthermore, LNP-Tmprss6 siRNA treatment of Hbb(th3/+) mice substantially improved the anemia by altering RBC survival and ineffective erythropoiesis. Our results indicate that pharmacologic manipulation of Tmprss6 with RNAi therapeutics isa practical approach to treating iron overload diseases associated with diminished hepcidin expression and may have efficacy in modifying disease-associated morbidities of -thalassemia intermedia.

(PDF same-day service: $19.90)

Accession: 051467493

Download citation: RISBibTeXText

PMID: 23223430

DOI: 10.1182/blood-2012-09-453977

Related references

An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe-/- mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia. 2013

Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia. American Journal of Hematology 90(4): 310-313, 2015

RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of β-thalassemia intermedia. American Journal of Hematology, 2018

Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia. Haematologica 101(1): E8-E11, 2016

Inhibition of heme oxygenase ameliorates anemia and reduces iron overload in β-thalassemia mouse model. Blood, 2017

Iron balance and the management of iron overload in beta-thalassemia intermedia. Birth Defects Original Article Series 23(5b): 29-33, 1988

Non-transferrin-bound plasma iron, iron overload and ineffective erythropoiesis in thalassemia major and intermedia. Blood 92(10 SUPPL 1 PART 1-2): 38B, Nov 15, 1998

Effect of Erythropoietin, Iron Deficiency and Iron Overload on Liver Matriptase-2 (TMPRSS6) Protein Content in Mice and Rats. Plos One 11(2): E0148540-E0148540, 2016

Iron overload in β-thalassemia intermedia: an emerging concern. Current Opinion in Hematology 20(3): 187-192, 2013

Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia. Hematology/Oncology Clinics of North America 24(6): 1089-1107, 2011

Radioautographic observations on iron absorption by the duodenum of mice with iron overload, iron deficiency, and x-linked anemia. Blood 42(1): 131-140, 1973

Iron overload and desferrioxamine chelation therapy in β-thalassemia intermedia. European Journal of Pediatrics 137(3): 267-271, 1981

Percutaneous excretion of iron and ferritin (through Al-hijamah) as a novel treatment for iron overload in beta-thalassemia major, hemochromatosis and sideroblastic anemia. Medical Hypotheses 83(2): 238-246, 2015

Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload. Infectious Disorders Drug Targets 15(2): 98-105, 2016

TMH-ferrocene induced iron overload in the murine model best mimics thalassemia major A comparison of four iron overloading methods. Blood 98(11 Part 1): 496a, November 16, 2001